Go to Top
INVENTOR LOGIN

Details

Project TitleCompact Biosensor for Neurological Diseases and Pain
Track Code2011-109
Short Description

Researchers at the University of New Mexico have developed a device including an optical fiber modified with quantum dots (QDs) for biosensing in the cerebral spinal fluid (CSF) in vivo, by characterizing matrix metalloproteinase (MMP) enzyme activity for identification and diagnosis of specific neurological diseases.

Abstract

This innovation hinges on the ability to distinguish real pain from not, which aids in the earlier detection and diagnostics of neurological diseases that affect MMP enzyme levels.

 
Tagspain, biomarker, neurodegenerative diseases, sclerosis
 
Posted DateSep 13, 2012

Researcher

Name
Erin Milligan
Marek Osinski
John Bryan Plumley

Manager

Name
Jovan Heusser

Background

Given existing pain treatments, which primarily target neurons, reduce pain by only ~25-40% in less than half of the 15 million patients suffering from chronic neuropathic pain in the US, underscores the significance and need for developing new methods to identify and investigate cellular processes beyond only neuronal function.  Of those pain drugs currently available, opioid analgesics are the gold standard despite addiction liabilities associated with opioid treatment.  There has been an increasing interest in matrix metalloproteinase (MMP) enzyme biosensing activity as a biomarker for ALC, as well as, several other neurological diseases including HIV and multiple sclerosis, where comparisons of the levels may elicit better and faster diagnosis of the specific disease.

Technology Description

Researchers at the University of New Mexico have developed a device including an optical fiber modified with quantum dots (QDs) for biosensing in the cerebral spinal fluid (CSF) in vivo, by characterizing matrix metalloproteinase (MMP) enzyme activity for identification and diagnosis of specific neurological diseases.

Advantages/Applications

  • Biomarker will enable early diagnosis and identification between neurological diseases including ALS, MS, and neurotrauma and from diseases that have similar symptoms like HIV and lime disease
  • Earlier diagnosis leads to treatment development, since treatment is likely more effective at the early onset of the disease
  • Method suitable for complex in vivo conditions and sensitive bioassays and diagnostics
  • Target fluorescence signal can be clearly separated from excitation light
  • Diagnostic tool to recognize true pain from psychological
  • May have ability to distinguish real pain from not, which aids in the earlier detection and diagnostics of neurological diseases that affect MMP enzyme levels

INQUIRES

STC has filed intellectual property on this exciting new technology and is currently exploring commercialization options. If you are interested in information about this or other technologies, please contact Arlene Mirabal at amirabal@stc.unm.edu or 505-272-7886.

Files

File Name Description
9,655,553 Issued Patent None Download
9,155,497 Issued Patent None Download

Intellectual Property

Patent Number Issue Date Type Country of Filing
9,655,553 May 23, 2017 Continuation United States
9,155,497 Oct 13, 2015 Utility United States